Selection from HEOR Bibliography
| Search criteria | ||||
| Malaysia |
||||
| Risk Factors and Medical Resource Utilization of Respiratory Syncytial Virus, Human Metapneumovirus and Influenza Related Hospitalizations in Adults – A Global Study During the 2017-2019 Epidemic Seasons (Hospitalized Acute Respiratory Tract Infection [HARTI] Study) | ||||
| Ann R Falsey, Edward E Walsh, Stacey House, Yannick Vandenijck, Xiaohui Ren, Sofia Keim, Diye Kang, Pascale Peeters, James Witek, Gabriela Ispas | ||||
| University Of Rochester School Of Medicine and Rochester Regional Health, Rochester, NY, United States; Washington University School of Medicine, St Louis, MO, United States; Janssen Infectious Diseases, Beerse, Belgium; IQVIA Real-World Solutions, Courbevoie, France; Janssen Research & Development, LLC, Titusville, NJ, United States | ||||
| , Article | ||||
| , Argentina, Australia, Brazil, Canada, France, Germany, Japan, Korea, Malaysia, Mexico, South Africa, USA | ||||
| Abstract: https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofab491/6381446 | ||||
| Condition | Year | Language | Analysis type | |
| , Infectious disease | 2021 | English | , Burden of illness, Clinical setting: hospital, Epidemiological study, Observational study, Patient questionnaire, Prospective study | |
| Budget impact analysis of Biphasic Insulin Aspart in the treatment of Type 2 Diabetes Mellitus in Malaysia: A Public Payer Perspective | ||||
| Tan SC1, Matzen P2, Yeo LN2 | ||||
| 1 IMS Asia Pacific, Singapore 2 Novo Nordisk Pharma Malysia, Kuala Lumpur, Malaysia | ||||
| ISPOR 6th Asia-Pacific Conference, Beijing, China, 6-9 September, 2014 |
||||
| , Poster | ||||
| , Malaysia | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Budget impact | |
| Estimating the Costs of Diabetes Mellitus: An Analysis in Malaysia | ||||
| Todorova L1, Hnoosh A2, Bloomfield E2, Shiu ML3 | ||||
| 1 Novo Nordisk International Operations, Zurich, Switzerland 2 IMS Health, London, UK 3 Novo Nordisk Pharma Operations (BAOS) Sdn. Bhd., Kuala Lumpur, Malaysia | ||||
| ISPOR 5th Asia-Pacific Conference, 2-4 September 2012, Taipei, Taiwan. |
||||
| , Abstract | ||||
| , Malaysia | ||||
| Abstract: http://www.ispor.org/conferences/Taipei0912/Posters2.aspx | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Cost analysis | |
| The cost-effectiveness of travoprost preserved with polyquad® in newly treated open-angle glaucoma patients in 7 Asian countries. | ||||
| Gerlier L1, Lamotte M1, Caputo J2, Tan R3 | ||||
| 1 IMS Health Consulting EMEA, Vilvoorde, Belgium 2 IMS Health Consulting Asia-Pacific, Singapore 3 ALCON, Asia-Pacific, Singapore | ||||
| 5th ISPOR Asia-Pacific Conference, 2012, September 2-4, Taipei, Taiwan |
||||
| , Abstract, Poster | ||||
| , India, Malaysia, Singapore, South Korea, Thailand | ||||
| Condition | Year | Language | Analysis type | |
| , Ophthalmology | 2012 | English | , Cost effectiveness | |
| Medical resource use and associated costs in open-angle glaucoma in 10 Asia-pacific countries. | ||||
| Gerlier L1, Lamotte M1, Caputo J2, Tan R3 | ||||
| 1 IMS Health Consulting EMEA, Vilvoorde, Belgium 2 IMS Health Consulting Asia-Pacific, Singapore 3 ALCON, Asia-Pacific, Singapore | ||||
| 5th ISPOR Asia-Pacific Conference, 2012, September 2-4, Taipei, Taiwan |
||||
| , Abstract, Poster | ||||
| , Australia, China, Hong Kong, India, Malaysia, New Zealand, Singapore, South Korea, Taiwan, Thailand | ||||
| Condition | Year | Language | Analysis type | |
| , Ophthalmology | 2012 | English | , Burden of illness | |
| Asthma control and its direct healthcare costs: findings using a derived Asthma Control Test (ACT) score in eight Asia-Pacific areas. | ||||
| Lai CKW1 Kuo S-H2 de Guia T3 Lloyd A4, Williams AE5, Spencer MD5 | ||||
| 1 Dept of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong 2 National Taiwan University Hospital, Taipei, Taiwan 3 Philippine Heart Centre, Quezon City, The Philippines 4 Fourth Hurdle Consulting Ltd, London, UK 5 GlaxoSmithKine R&D, Greenford, UK | ||||
| European Respiratory Review 2006; 15:(98): 24-29 |
||||
| , Manuscript in preparation | ||||
| , China, Hong Kong, Malaysia, Philippines, Singapore, Taiwan, Vietnam | ||||
| Condition | Year | Language | Analysis type | |
| , Respiratory disease | 2006 | English | , Cost of illness | |